tetano
Editor, Senior Moderator
Infect Chemother
. 2023 Mar;55(1):99-104.
doi: 10.3947/ic.2022.0132.
Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea
Heeji Lim[SUP] 1 [/SUP], Sundong Jang[SUP] 1 [/SUP], Hyun Ju In[SUP] 1 [/SUP], Kwangwook Kim[SUP] 1 [/SUP], Eun Bee Choi[SUP] 1 [/SUP], Soo Ji Kim[SUP] 1 [/SUP], Hye Jung Lim[SUP] 1 [/SUP], Min Su Yim[SUP] 1 [/SUP], In-Ohk Ouh[SUP] 1 [/SUP], Byung Chul Kim[SUP] 1 [/SUP], Hyeon Nam Do[SUP] 2 [/SUP], June-Woo Lee[SUP] 2 [/SUP], Byoungguk Kim[SUP] 2 [/SUP], Yoo-Kyoung Lee[SUP] 3 [/SUP]
Affiliations
Abstract
The immunogenicity of a heterologous vaccination regimen consisting of ChAdOx1 nCoV-19 (a chimpanzee adenovirus-vectored vaccine) followed by mRNA-1273 (a lipid-nanoparticle-encapsulated mRNA-based vaccine) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically the omicron variant (B.1.1.529), is poorly studied. The aim of this study was to evaluate the neutralizing antibody activity and immunogenicity of heterologous ChAdOx1 nCoV-19 and mRNA-1273 prime-boost vaccination against wild-type (BetaCoV/Korea/KCDC03/2020), alpha, beta, gamma, delta, and omicron variants of SARS-CoV-2 in Korea. A 50% neutralizing dilution (ND50) titer was determined in serum samples using the plaque reduction neutralization test. Antibody titer decreased significantly at 3 months compared with that at 2 weeks after the 2nd dose. On comparing the ND50 titers for the above-mentioned variants of concerns, it was observed that the ND50 titer for the omicron variant was the lowest. This study provides insights into cross-vaccination effects and can be useful for further vaccination strategies in Korea.
Keywords: COVID-19 vaccine; Heterologous vaccination; Immunity; Korea; Omicron variant.
. 2023 Mar;55(1):99-104.
doi: 10.3947/ic.2022.0132.
Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea
Heeji Lim[SUP] 1 [/SUP], Sundong Jang[SUP] 1 [/SUP], Hyun Ju In[SUP] 1 [/SUP], Kwangwook Kim[SUP] 1 [/SUP], Eun Bee Choi[SUP] 1 [/SUP], Soo Ji Kim[SUP] 1 [/SUP], Hye Jung Lim[SUP] 1 [/SUP], Min Su Yim[SUP] 1 [/SUP], In-Ohk Ouh[SUP] 1 [/SUP], Byung Chul Kim[SUP] 1 [/SUP], Hyeon Nam Do[SUP] 2 [/SUP], June-Woo Lee[SUP] 2 [/SUP], Byoungguk Kim[SUP] 2 [/SUP], Yoo-Kyoung Lee[SUP] 3 [/SUP]
Affiliations
- PMID: 37021427
- DOI: 10.3947/ic.2022.0132
Abstract
The immunogenicity of a heterologous vaccination regimen consisting of ChAdOx1 nCoV-19 (a chimpanzee adenovirus-vectored vaccine) followed by mRNA-1273 (a lipid-nanoparticle-encapsulated mRNA-based vaccine) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically the omicron variant (B.1.1.529), is poorly studied. The aim of this study was to evaluate the neutralizing antibody activity and immunogenicity of heterologous ChAdOx1 nCoV-19 and mRNA-1273 prime-boost vaccination against wild-type (BetaCoV/Korea/KCDC03/2020), alpha, beta, gamma, delta, and omicron variants of SARS-CoV-2 in Korea. A 50% neutralizing dilution (ND50) titer was determined in serum samples using the plaque reduction neutralization test. Antibody titer decreased significantly at 3 months compared with that at 2 weeks after the 2nd dose. On comparing the ND50 titers for the above-mentioned variants of concerns, it was observed that the ND50 titer for the omicron variant was the lowest. This study provides insights into cross-vaccination effects and can be useful for further vaccination strategies in Korea.
Keywords: COVID-19 vaccine; Heterologous vaccination; Immunity; Korea; Omicron variant.